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Abstract
Background: Imatinib mesylate, a selective inhibitor of Abl tyrosine kinase, is efficacious in
treating chronic myeloid leukaemia (CML) and Ph+ acute lymphoblastic leukaemia (ALL). However,
most advanced-phase CML and Ph+ ALL patients relapse on Imatinib therapy. Several mechanisms
of refractoriness have been reported, including the activation of the Src-family kinases (SFK). Here,
we investigated the biological effect of the new specific dual Src/Abl kinase inhibitor AZD0530 on
Ph+ leukaemic cells.
Methods: Cell lines used included BV173 (CML in myeloid blast crisis), SEM t(4;11), Ba/F3 (IL-3
dependent murine pro B), p185Bcr-Abl infected Ba/F3 cells, p185Bcr-Abl mutant infected Ba/F3 cells,
SupB15 (Ph+ ALL) and Imatinib resistant SupB15 (RTSupB15) (Ph+ ALL) cells. Cells were exposed
to AZD0530 and Imatinib. Cell proliferation, apoptosis, survival and signalling pathways were
assessed by dye exclusion, flow cytometry and Western blotting respectively.
Results: AZD0530 specifically inhibited the growth of, and induced apoptosis in CML and Ph+ ALL
cells in a dose dependent manner, but showed only marginal effects on Ph- ALL cells. Resistance to
Imatinib due to the mutation Y253F in p185Bcr-Abl was overcome by AZD0530. Combination of
AZD0530 and Imatinib showed an additive inhibitory effect on the proliferation of CML BV173 cells
but not on Ph+ ALL SupB15 cells. An ongoing transphosphorylation was demonstrated between
SFKs and Bcr-Abl. AZD0530 significantly down-regulated the activation of survival signalling
pathways in Ph+ cells, resistant or sensitive to Imatinib, with the exception of the RTSupB15.
Conclusion: Our results indicate that AZD0530 targets both Src and Bcr-Abl kinase activity and
reduces the leukaemic maintenance by Bcr-Abl.
Background
The cytogenetic hallmark of chronic myeloid leukaemia
(CML) and a subset of acute lymphoblastic leukaemia
(ALL) is the Philadelphia (Ph) chromosome. It is a short-
ened chromosome 22, generated by a reciprocal transloca-
tion between chromosome 9 and 22 t(9;22)(q34;q11)
[1].
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The most exciting breakthrough in the treatment of Ph+
leukaemias has been the development of Imatinib as an
orally bioavailable therapeutic agent [2]. Although Imat-
inib produces high rates of clinical and cytogenetic
responses in the chronic phase of CML, the onset of resist-
ance and clinical relapse in the advanced phases of CML
and Ph+ ALL is rapid [3,4]. The main mechanisms of
resistance to Imatinib include Bcr-Abl dependent mecha-
nisms such as amplification or mutations in the Abl por-
tion of the Bcr-Abl gene.
Recent reports have demonstrated a requirement for Src
kinase activity in Bcr-Abl transformation and oncogenic
signal transduction [5]. Bcr-Abl expressed in myeloid cells
activates both Hck and Lyn, suggesting that these kinases
might play a role in the pathogenesis of CML [6]. In Ph+
ALL, Bcr-Abl seems to stimulate different Src family
kinases (SFK) such as Blk, Lck and Fyn [7].
In Imatinib resistant patients, a non-Bcr-Abl dependent
up-regulation in SFK expression has been observed [8].
Up-regulation of the Src family proteins Hck and Lyn,
have been shown to correlate with disease progression
and resistance in cell lines and patients treated with Imat-
inib [9].
The NH2-terminal portion of Abl bears 42% identity to
the SFK and shares a similar domain organisation [10]. Src
inhibitors have been shown to bind to Bcr-Abl irrespective
of the Abl conformation [11]. Moreover, Imatinib does
not inhibit SFK directly, further supporting the possible
importance of SFKs in the development of clinical Imat-
inib resistance [12].
Based on this rationale, we investigated the effects of a
new dual Src/Abl kinase inhibitor, AZD0530 with the aim
of inhibiting both Src and Bcr-Abl kinases irrespective of
their conformations to explore the possibility of overcom-
ing resistance to Imatinib with the use of AZD0530.
Methods
p185Bcr-Abl mutant constructs
Bcr-Abl cDNAs harbouring E255K, T315I, and Y253F
mutations were obtained by site-directed mutagenesis
using a modification of Stratagene's  QuickChange site-
directed mutagenesis Kit protocol. For the generation of
mutated plasmid DNA the following primers were used
(mutated base pairs are underlined): Mut255_Fwd: 5'-G
GGG CCA GTA CGGG GAA ATG TAC GAG GGC GTG-3',
and Mut255_rev: 5'-CAC GCC CTC GTA CAC TTT CCC
GTA CTG GC-3' (pEp185Bcr-AblMutE255K); Mut315_Fwd:
5'-GTT CTA TAT CAT CAT AGA GTT CAT GAC CTA C-3'
and Mut315_rev: 5'-GGT CAT GAA CTC TAT GAT GAT
ATA GAA CGG-3' (pEp185Bcr-AblMutT315I); and
Mut253_Fwd: 5'-GGG CGG GGG CCA GTT TGG GGA
GGT GTA CGA GGG C-3'and Mut253_rev: 5'-CCT CGT
ACA CCT CCC CAA ACT GGC CCC CGC CCA GC-3'
(pEp185Bcr-AblMutY253F). Mutated plasmid DNA was
sequenced using the primer Bcr-Abl 2436: 5'-CTT GAT
GGA GAA CTT GTT GTA GGC-3'. All PCR-products were
controlled for the presence of mutations by sequencing.
The resulting cDNAs were cloned into the pENTR1A vec-
tor for further recombination into the PINCO vector as
described in Beissert et al. 2008 [13] using the Gateway
LR-clonase enzyme kit (Invitrogen, Karslruhe, Germany).
Cell culture, Drug treatment
Cells were cultured at 37°C in 5% CO2 in humidified
atmosphere. Human leukaemic cell lines, BV173, SEM,
SupB15, and murine Ba/F3 were obtained from the Ger-
man Collection of Microorganisms and Cell Cultures
(DSMZ, Braunschweig, Germany). The ecotropic packag-
ing cells Phoenix were obtained from Harald von Melch-
ner at the Medical School of Johann Wolfgang Goethe,
Frankfurt. Ba/F3 were cultured in RPMI 1640 (Invitrogen)
supplemented with 10% fetal calf serum (FCS) (Invitro-
gen), 10ng/ml murine IL-3 (Cell Concepts, Umkirch, Ger-
many), 1% Glutamine and 1% Penicillin/Streptomycin
(40 U/ml Penicillin, 40 μg/ml Streptomycin) (Invitrogen).
BV173, Ba/F3PINCOp185Bcr-Abl, Ba/F3PINCOp185Bcr-
AblMutE255K, Ba/F3PINCOp185Bcr-AblMut T315I, Ba/
F3PINCOp185Bcr-AblMutY253F were maintained in the
same medium but without IL-3. SEM cells were cultured
in Iscove's MDM supplemented with 10% FCS, 1%
Glutamine and 1% Penicillin/Streptomycin. WTSupB15
were maintained in RPMI 1640 supplemented with 15%
FCS, 1% Glutamine and 1% Penicillin/Streptomycin.
RTSupB15 were cultured in supplemented RPMI 1640
medium with the addition of 1 μM Imatinib.
Retroviral infection
Ecotropic Phoenix packaging cells were transiently trans-
fected with the indicated retroviral vectors as described
before [14]. Transfection efficiency of the packaging cells
was assessed by the detection of the percentage of green
fluorescent protein (GFP) positive cells through fluores-
cence-activated cell sorting (FACS) analysis. Retroviral
supernatant was collected at days 2 and 3 after transfec-
tion, shock-frozen in liquid nitrogen and stored at -80°C.
For the infection, the retroviral supernatant was thawed
on ice. Target cells were plated onto retronectin-coated
(Takara-Shuzo, Shiga, Japan) non tissue culture treated
24-well plates and exposed to the retroviral supernatant
for 3 hours at 37°C in the presence of 4 μg/mL polybrene
(Sigma-Aldrich, Steinheim, Germany). Cells were centri-
fuged at 2200 rpm for 45 minutes. Infection was repeated
three times and infection efficiency had to be at least 70%
for each sample as assessed by the detection of GFP posi-
tive cells by FACS. Differences of transduction efficiency
between the samples did not exceed 10%. For IL-3 with-BMC Cancer 2009, 9:53 http://www.biomedcentral.com/1471-2407/9/53
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drawal, cells were washed twice with PBS, and plated at 1
× 105cells/ml in medium without IL-3.
Proliferation and apoptosis assays
Viability of cells was detected by the trypan blue dye exclu-
sion and apoptosis was determined by 7-AAD staining as
described previously [15].
Western blot
Western blot analysis was performed accordingly to
widely used protocols. The following primary antibodies
were used: Rabbit polyclonal antibodies included anti-
phospho-c-Abl (Tyr245)-antibody (α-p-c-Abl), anti-phos-
pho-Akt (Tyr326)-antibody (α-p-Akt), anti-Akt-antibody
(α-Akt), anti-p44/p42 MAP Kinase-antibody (α-p44/42),
anti-Hck-antibody (α-Hck), anti-phospho-Lyn (Tyr507)-
antibody (α-p-Lyn), anti-Lyn-antibody (α-Lyn), anti-
PARP-antibody (α-PARP), anti-phospho-Src family
(Tyr416)-antibody (α-p-Src), Polyclonal rabbit anti-Stat5-
antibody (α-Stat5). Monoclonal rabbit anti-Src (clone
36D10)-IgG-antibody (α-Src) and monoclonal mouse
anti-phospho-Stat5 (Tyr694) (clone 14H2) IgG1-anti-
body (α-p-Stat5) (all from Cell Signaling Technologies,
Frankfurt, Germany). Monoclonal mouse anti-c-Abl
(clone 24-11)-IgG1-antibody (α-Abl), polyclonal rabbit
anti-c-Abl (clone K-12)-IgG-antibody (α-Abl), mono-
clonal mouse anti-phospho-Erk (clone E-4)-IgG2a-anti-
body (α-p-Erk), polyclonal goat anti-p-Hck (Tyr 411)-
IgG-antibody (α-p-Hck), polyclonal goat anti-Hck (clone
N-30)-antibody (α-Hck), and polyclonal goat anti-Hck
(clone M-28)-IgG-antibody (α-Hck) were purchased from
Santa Cruz (Heidelberg, Germany). Monoclonal mouse
anti-Hck (clone 18)-IgG1-antibody (α-Hck) and mono-
clonal mouse anti-Stat5 (clone 89)-IgG2b-antibody (α-
Stat5) were from Becton Dickinson (Heidelberg, Germany).
Secondary polyclonal goat-anti-rabbit-IgG-HRP conju-
gate-antibody, polyclonal goat-anti-mouse-IgG-HRP con-
jugate-antibody, and polyclonal mouse-anti-goat-IgG-
HRP conjugate-antibody were purchased from Dianova
GmbH, (Hamburg, Germany).
Statistical analysis
Data were compared by a two-tailed Student t test; p val-
ues < 0.05 were considered to be significant.
Results
AZD0530 specifically blocks proliferation of Ph+ cells
To determine the effect and specificity of AZD0530 on Src
and Bcr-Abl mediated growth inhibition of Ph+ cells, the
CML blast cell line BV173, was treated with various con-
centrations of AZD0530, and cell proliferation was meas-
ured by trypan blue exclusion of viable cells. As control for
specificity the Ph- ALL cell line SEM, was used. Figure 1A
shows that incubation with AZD0530, resulted in a dose-
dependent decrease in cell proliferation of BV173 cells in
contrast to the SEM cells over a three-day incubation
period. In the BV173 cells, growth inhibition could be
observed as from 0,5 μM AZD0530 when compared to
DMSO treated cells. Proliferation in the SEM cells was not
affected in the presence of 5 μM AZD0530 when com-
pared to control cells.
These data show that AZD0530 is able to specifically
block growth of Ph+ patient derived cells.
AZD0530 does not overcome resistance to Imatinib in the 
RTSupB15
Clinical relapse and resistance to Imatinib has been
shown to develop rapidly in the advanced phases of CML
and Ph+ ALL patients mainly due to Bcr-Abl-dependent
mechanisms such as amplification or mutations in the
Abl portion of the Bcr-Abl gene. To examine the role of
other potential mechanisms of Imatinib-resistance, the
Imatinib-resistant Ph+ ALL cells RTSupB15 were estab-
lished by long term culture of WTSupB15 cells with
increasing amounts of Imatinib [16]. The RTSupB15 were
viable and grew well in the presence of 1 μM Imatinib as
compared to the parental WTSupB15 cells (data not
shown). Treatment of RTSupB15 with Imatinib led to the
down-regulation of the Bcr-Abl activity suggesting a mech-
anism independent of the kinase activity of Bcr-Abl. In
RTSupB15 cells, no mutations were detectable in Bcr-Abl
exons 4, 6, and 7 upon analysis. Cytogenetically
WTSupB15 and RTSupB15 presented no differences [16].
As shown in Figure 1B, proliferation of the parental
WTSupB15 cells was blocked in the presence of AZD0530,
when compared to the Imatinib resistant cell line
RTSupB15 that did not respond to treatment with
AZD0530.
In summary, these data show that AZD0530 is unable to
overcome non-mutational Imatinib resistance.
AZD0530 blocks the proliferation of p185Bcr-Abl expressing 
Ba/F3 cells as well as Bcr-Abl expressing Ba/F3 cells 
harbouring mutations which induce Imatinib resistance
Recent data have demonstrated that Bcr-Abl-dependent
cell lines are sensitive to growth arrest induced by dual
Src/Abl kinase as well as Src selective kinase inhibitors
such as Dasatinib, PP2 and A-419259 [5]. To investigate
the effect of AZD0530 on cells that depend on Bcr-Abl for
their survival we treated Ba/F3 cells, which were rendered
factor-independent by the expression of Bcr-Abl with
AZD0530. Empty vector transduced Ba/F3 cells grown in
the presence of IL-3 were not inhibited upon exposure to
AZD0530 (Data not shown). In contrast Ba/F3p185Bcr-Abl
showed a concentration-dependent growth inhibition.BMC Cancer 2009, 9:53 http://www.biomedcentral.com/1471-2407/9/53
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Effects of AZD0530 on proliferation Figure 1
Effects of AZD0530 on proliferation. A AZD0530 specifically blocks the proliferation of Ph+ BV173 cells in a dose 
dependent manner, while the proliferation of the Ph- SEM cells is not markedly affected. B AZD0530 inhibited proliferation of 
WTSupB15, in a dose-dependent way. No effect was observed on the proliferation of RTSupB15 upon treatment with 
AZD0530. C AZD0530 inhibited the proliferation of Ba/F3 cells expressing WTp185Bcr-Abl and the Bcr-Abl Mut Y253F. Ba/F3 
cells expressing the Bcr-Abl Mut E255K were less sensitive to AZD0530 as compared to Mut Y253F and cells expressing Bcr-
Abl Mut T315I were stable in the presence of AZD0530. All cell lines were treated with the indicated concentrations of 
AZD0530 for three days and proliferation was determined by trypan blue exclusion of viable cells. Results are the mean values 
of 3 independent experiments carried out in duplicates +/- S.D.BMC Cancer 2009, 9:53 http://www.biomedcentral.com/1471-2407/9/53
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Taken together these data show that AZD0530 targets spe-
cifically the Bcr-Abl dependent signalling. To investigate
the effects of AZD0530 on Bcr-Abl harbouring mutations
conferring Imatinib-resistance (Y253F, E255K and T315I)
Ba/F3 cells expressing these mutants were treated with the
dual Src/Abl kinase inhibitor AZD0530, and proliferation
was assessed comparing them with the Ba/F3 infected
p185Bcr-Abl cells treated in a similar manner (Figure 1C).
Here we show that proliferation of p185Bcr-Abl and Mut
Y253F was inhibited by the use of AZD0530 (Figure 1C,
see Additional files 1 and 2). Mut E255K was less sensitive
to AZD0530 as compared to Mut Y253F, and needed
higher concentrations of the inhibitor demonstrated by
an altered dose-response with Mut E255K cells. Prolifera-
tion of Mut T315I was not affected by the presence of
AZD0530.
Taken together these results indicate that AZD0530 is able
to overcome resistance of Bcr-Abl Mut Y253F and E255K
but not of T315I.
AZD0530 specifically induces apoptosis in Ph+ cells
To answer the question whether the dose-dependent inhi-
bition of Ph+ cell proliferation by AZD0530 was associ-
ated with the induction of apoptosis, both BV173 (Ph+)
and SEM (Ph-) cell lines were treated in parallel with
increasing concentrations of AZD0530 and Imatinib for
three days and apoptosis was measured by 7-AAD stain-
ing. At the protein level, poly(ADP-ribose)polymerase
(PARP) cleavage was used as a sign of apoptosis, and was
examined in whole cell lysates by immunoblotting. As
shown in Figure 2A, BV173 cells underwent a dose-
dependent induction of apoptosis of 20%, 54% and 55%
in the presence of 0.5 μM, 2 μM and 5 μM AZD0530
respectively. In contrast to BV173 cells, only 11% induc-
tion of apoptosis was reached in the SEM cells, even at the
highest concentration of 5 μM AZD0530. In the SEM cells,
neither AZD0530 nor Imatinib induced significant PARP
cleavage, whereas in BV173 cells, PARP was already
cleaved in the presence of 0.5 μM AZD0530 and 0.5 μM
Imatinib. The induction of PARP cleavage in the BV173
cells correlated well with apoptosis measurement.
These results confirmed that the inhibition of SFKs and
Bcr-Abl by both compounds was associated with the
induction of apoptosis and was Bcr-Abl dependent.
AZD0530 does not induce apoptosis in Imatinib resistant 
RTSupB15 cells
To further investigate the influence of AZD0530, apopto-
sis measurement and PARP cleavage were assessed in the
RTSupB15 cells and the results were compared to that of
the parental WTSupB15 cell line (Figure 2B). In the
WTSupB15 cells, apoptosis measurement by 7-AAD stain-
ing (IC50 of 0.5 μM) correlated well with PARP cleavage
(bottom panel), with a strong effect of 2 μM ADZ0530.
This is contrary to the RTSupB15 cells with not more than
20% of cells undergoing apoptosis at the highest concen-
tration (5 μM AZD0530) used, as compared to the control
cells. This could be confirmed by a lack of PARP cleavage
(bottom panel).
AZD0530 inhibits SFK activity at concentrations that cause 
growth arrest and induce apoptosis in Bcr-Abl positive cells
To determine the effects of AZD0530 and Imatinib on SFK
activity in the CML cell line BV173 cells were exposed to
the same inhibitor concentrations used in the prolifera-
tion and apoptosis assays (Figure 3A). Whole cell lysates
were analysed by Western blot using an antibody specific
for the activated form of the Src family of tyrosine kinases.
Lysates were additionally probed for phosphorylated Bcr-
Abl, to further investigate if the activation status of Bcr-Abl
was correlating with growth inhibition and apoptosis.
SEM cells were used as control. Figure 3A shows that in
BV173 cells 0.5 μM AZD0530 and 0.5 μM Imatinib
strongly inhibited both Src phosphorylation of all SFKs
and Hck phosphorylation, but higher concentrations of
both inhibitors were needed to inhibit phosphorylation
of Bcr-Abl. Inhibition of SFK phosphorylation and Hck
phosphorylation by AZD0530 in BV173 cells was seen at
concentrations which led to apoptosis induction and
reduced cell proliferation.
In contrast SFK and Hck inhibition in SEM cells was
observed in the presence of AZD0530 but not Imatinib,
and neither led to growth inhibition nor apoptosis induc-
tion.
Bcr-Abl is up-stream to SFK in CML-BV173 cells but down-
stream in ALL-SupB15 cells
In Ph+ leukaemic cells, it is not clear if the interaction
between Bcr-Abl and SFKs is solely due to activation of Src
kinases by Bcr-Abl, activation of Bcr-Abl by SFKs or, if
there exists a transphosphorylation mechanism between
both tyrosine kinases.
To investigate the influence of Abl kinase inhibition on
SFK activation we exposed BV173 cells to Imatinib. Figure
3A shows that treatment of BV173 with Imatinib led to a
complete dephosphorylation of both Bcr-Abl and SFKs (in
particular Hck). These findings suggest that the Src kinases
are a substrate of Bcr-Abl in BV173 cells. A similar phe-
nomenon was seen in Imatinib resistant Ba/F3MutT253F
cells (see Additional file 2).
It has already been shown that Hck, Lyn, Fyn and Fgr each
bind the kinase domain, at the C-terminal tail, and SH3/
SH2 region of Bcr-Abl [5]. It is known that the Bcr-Abl-
Hck interaction is independent of catalytic activity [17].
Furthermore, Hck, Lyn and Fyn strongly phosphorylateBMC Cancer 2009, 9:53 http://www.biomedcentral.com/1471-2407/9/53
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Apoptosis induction by AZD0530 Figure 2
Apoptosis induction by AZD0530. A Inhibition of SFK and Bcr-Abl by AZD0530 and Imatinib leads to a Bcr-Abl-depend-
ent induction of apoptosis, as seen in BV173 (Ph+) versus SEM (Ph-) cell lines. One representative experiment out of 3 is given. 
B Induction of apoptosis in WTSupB15 cells and not in RTSupB15 cells. All four cell lines (BV173 (Ph+), SEM (Ph-), WTSupB15 
(Ph +) and RTSupB15 (Ph+ Imatinib resistant)) were treated with increasing concentrations of both compounds for three days. 
The percentage of apoptotic cells was measured by staining with 7-AAD. Results represent the mean values of three independ-
ent experiments +/- SD. For PARP cleavage, cells were treated for three days and immunoblotted. Intact (116 kDa) and 
cleaved (85 kDa) PARP are shown. Equal protein loading was monitored by probing tubulin on the same membrane. One rep-
resentative experiment out of 3 is given.BMC Cancer 2009, 9:53 http://www.biomedcentral.com/1471-2407/9/53
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Cell-type-specific effect of AZD0530 Figure 3
Cell-type-specific effect of AZD0530. A BV173 (Ph+) and SEM (Ph-) cells were incubated with the indicated concentra-
tions of AZD0530 and Imatinib for three days. Whole cell lysates were probed for activated SFKs, phosphorylated Hck and the 
activated form of Bcr-Abl. BV173 and WTSupB15 samples in the SEM (Ph-) panel were used as a control for the detection of 
Bcr-Abl and phosphorylated Bcr-Abl. Tubulin was used as control for protein loading. (1) In BV173 cells SFK activity but not 
Bcr-Abl activation was inhibited at concentrations that cause growth arrest and induce apoptosis. (2) In BV173 cells, SFKs were 
shown to act downstream of Bcr-Abl. B Bcr-Abl as substrate of SFKs. WTSupB15 (left) and RTSupB15 (right), were treated 
with AZD0530 and Imatinib for three days. Whole cell lysates were prepared and probed for activated SFKs, phosphorylated 
Hck and the activated form of Bcr-Abl. Tubulin was used as a control for equal protein loading. In both cell lines Bcr-Abl was 
shown to be transphosphorylated by SFKs.BMC Cancer 2009, 9:53 http://www.biomedcentral.com/1471-2407/9/53
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recombinant, purified Abl SH3-SH2 protein in vitro [5].
These findings provide an argument for the fact that SFKs
interact with and promote Bcr-Abl leukaemogenesis. This
hypothesis was investigated in Imatinib sensitive and
resistant cells. To this effect, the Imatinib resistant cell line
RTSupB15 and its parental wild type cell line WTSupB15
were exposed to AZD0530 and Imatinib (Figure 3B).
Whole cell lysates were probed with antibodies to the acti-
vated forms of Bcr-Abl and Src kinases. In both cell lines,
activated Bcr-Abl was inhibited by both compounds, but
higher concentrations of Imatinib were needed in the
RTSupB15 cells when compared to WTSupB15 cells. The
SFKs were dephosphorylated by AZD0530 but not by
Imatinib in both cell lines (WTSupB15 and RTSupB15).
This provides evidence that Bcr-Abl acts downstream of
Src kinases in RTSupB15 as well as WTSupB15 and
explains why dephosphorylation of Bcr-Abl did not affect
the activity of the Src kinases.
AZD0530 blocks the activation of Stat5, Erk and PI3K/Akt 
specifically in Bcr-Abl positive cells
Activation of the Raf/Mek/Erk, PI3K/Akt and Stat path-
ways synergize to promote Ph+ leukaemic cell growth. To
investigate if inactivation of Src kinases and Bcr-Abl by
AZD0530 could interfere with the leukaemic survival sig-
nalling pathways, lysates from BV173 cells treated with
AZD0530 or Imatinib were probed with antibodies (acti-
vated and whole protein) against Stat5, Erk, and Akt
kinases. Results were compared to Ph- SEM cells (Figure
4). In the BV173 cells, both compounds inhibited phos-
phorylation of Stat5, Erk and Akt kinases. This correlated
well with the stronger effect on the inhibition of SFKs.
These results support the idea that the Src kinases couple
Bcr-Abl to its substrate proteins, and AZD0530 may target
more specifically the Src kinases. Neither AZD0530 nor
Imatinib affected the activation of all three proteins in the
SEM cells.
AZD0530 inhibits survival signalling pathways involved in Bcr-Abl leukaemogenesis Figure 4
AZD0530 inhibits survival signalling pathways involved in Bcr-Abl leukaemogenesis. Whole cell lysates from 
AZD0530 and Imatinib treated BV173 cells (left) and SEM cells (right) were probed with antibodies (phosphorylated and non-
phosphorylated forms) against Akt, Stat5 and Erk. Specificity of both inhibitors to Bcr-Abl was tested by comparing results of 
BV173 and SEM cells treated under similar conditions. In BV173 cells the activation of Akt, Stat5 and Erk was inhibited by 
AZD0530 and Imatinib, in contrast to SEM cells which showed no regulation of all three proteins. One representative experi-
ment out of 3 is given.BMC Cancer 2009, 9:53 http://www.biomedcentral.com/1471-2407/9/53
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Combining AZD0530 with Imatinib has an additive effect 
on BV173 cells
Combination therapy of Imatinib with an inhibitor of
Imatinib-resistant Bcr-Abl is frequently used to prevent
emergence of resistance. Dual Src/Abl kinase inhibitors
exhibit outstanding in vitro inhibitory profiles against
Imatinib resistance due to Bcr-Abl mutations and resist-
ance independent of Bcr-Abl [11]. To evaluate this strat-
egy, cells were treated with combinations of AZD0530
(0.1 μM, 0.5 μM, 1 μM) and Imatinib (0.1 μM, 0.5 μM)
and compared to the untreated control cells (Figure 5).
Growth inhibition was analysed using proliferation assays
as described previously [15]. An additive effect was seen
for BV173 cells, using 0.1 μM Imatinib and 1 μM
AZD0530 (0.6 × 106 cells/ml) compared to the single
agents alone (0.1 μM Imatinib (1.23 × 106 cells/ml) and 1
μM AZD0530 (0.8 × 106 cells/ml))(Figure 5A). No major
difference was seen upon treatment of the ALL cell lines
WTSupB15 (Figure 5B) and RTSupB15 (Figure 5C)
between single agents and combinations of AZD0530 and
Imatinib.
Discussion and conclusion
Recent reports have demonstrated a requirement for Src
kinase activity in Bcr-Abl transformation and oncogenic
signal transduction [5].
Here, we present AZD0530, a new, orally administered,
potent and highly selective dual Src/Abl kinase inhibitor,
whose effects have been investigated in solid tumours
[18]. In this study, we demonstrated that AZD0530 specif-
ically inhibits the growth of CML cells and Ph+ ALL cells
in a dose dependent manner, but had little or no effect on
Ph- ALL cells. AZD0530 inhibited the growth of Imatinib
Anti-proliferative effect of AZD0530 in combination with Imatinib Figure 5
Anti-proliferative effect of AZD0530 in combination with Imatinib. Effects of AZD0530 and Imatinib as single agents 
or in combination on the proliferation of BV173 (A), parental WTSupB15 (B) and Imatinib resistant RTSupB15 (C) cell lines. 
Combining AZD0530 with Imatinib had an additive effect only in BV173 cells. All three cell lines were plated in duplicates at 
the indicated concentrations, and proliferation was assessed after three days by dye exclusion of viable cells. Results represent 
the mean of 3 independent experiments +/- S.D.BMC Cancer 2009, 9:53 http://www.biomedcentral.com/1471-2407/9/53
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resistant Ba/F3 expressing MutY253F and MutE255K cells.
This could be explained by the fact that substitution of
Threonine by Phenylalanine (MutY253F) and Glutamine
by Lysine (MutE255K) distorted the conformation needed
by Imatinib to attach to Bcr-Abl in this cells, but such a
conformation was not needed by AZD0530. This indi-
cates that this compound could be used to overcome
resistance to Imatinib due to mutations, in Ph+ cells.
A significant induction of apoptosis in the Ph+ ALL cell
line WTSupB15 occurred at lower concentrations (0.5
μM) when compared to the CML cell line, BV173 (2 μM).
It could be concluded that the SFK inhibited by AZD0530,
contribute to a greater extent to proliferation and survival
in Ph+ ALL cells than the CML cells. Neither proliferation
nor apoptosis induction was influenced by AZD0530 in
the Imatinib resistant RTSupB15 cells (Ph+ ALL). This
confirmed that resistance to Imatinib in these cells is not
Src dependent.
Analysis of the mechanisms of action of AZD0530
showed that higher concentrations of AZD0530 and Imat-
inib were needed to inhibit the activation of Bcr-Abl,
when compared to the concentrations needed to inhibit
activated SFK in BV173 cells. Growth and survival of the
Ph- ALL cell line SEM was not influenced by both com-
pounds, though AZD0530 inhibited the activation of
SFKs in these cells. This also confirmed that Src kinases
influence the survival of Bcr-Abl positive cells.
In this study, it could not be clearly defined if the inhibi-
tory effects of AZD0530 were a result of its direct effect on
Src kinases, Bcr-Abl or on both kinases. Since Src kinases
are inhibited by Imatinib in BV173 cells but not in Ph-
SEM cells, it could be hypothesized that SFKs are
transphosphorylated and acting downstream of Bcr-Abl in
the CML blast cell line BV173. In contrast to the BV173
cells, in the SupB15 cells, Bcr-Abl was described as acting
downstream of SFKs. In SupB15 cells, AZD0530 down-
regulated the activated forms of both SFK and Bcr-Abl, in
contrast to Imatinib, which inhibited only the activity of
Bcr-Abl, and not SFK. This can be explained by the fact
that inhibition of Bcr-Abl alone (by Imatinib) has no
effect on SFK. Hence Bcr-Abl can only be activated by SFK
in this cell line and not vice versa.
In BV173 cells, both AZD0530 and Imatinib blocked Erk,
Akt and Stat5 activation at concentrations that inhibited
SFKs but did not affect Bcr-Abl tyrosine phosphorylation.
This was an indication that SFKs coupled Bcr-Abl to its
survival and signalling molecules, enhancing disease pro-
gression. This was in contrast to SEM cells in which
AZD0530 inhibited the activation of SFKs but not the acti-
vation of Erk, Akt and Stat5. This confirmed that the activ-
ity of these substrate proteins was Src independent in Ph-
cells.
Treatment of the BV173 cells but not the WTSupB15 cells
with a combination of AZD0530 and Imatinib yielded an
additive antiproliferative effect, when compared to the
single agents alone. Taken together these data suggest an
additional effect of AZD0530 on Imatinib in BV173 cells
that seems to be cell type specific.
In advanced Ph+ leukaemia (Ph+ ALL or CML blast crisis)
clinical trials with Imatinib have shown that Bcr-Abl inhi-
bition is not sufficient to prevent disease progression or to
restrict expansion of resistant cells. This has necessitated
the development of treatment regimens, where single
compounds target both Bcr-Abl and its substrate proteins
as seen in the case of AZD0530.
In recent investigations we have been able to show that in
primary patient cells resistant to Imatinib, Src kinase inhi-
bition is more effective in the presence of AZD0530 when
compared to the Imatinib treated cells. In summary, our
in vitro data strongly suggest that inhibition of SFK aug-
ments growth inhibition achieved by Bcr-Abl kinase
inhibitors. Two of the most frequent domain mutations,
which show resistance to Imatinib (MutY253F and
E255K), responded to treatment with AZD0530.
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AZD0530 inhibits Bcr-Abl activation and its downstream signalling 
pathways in Imatinib resistance Ba/F3MutT253F cells. The Imatinib 
resistant cell line Ba/F3MutT253F was treated with AZD0530 and Imat-
inib for three days. Whole cell lysates were blotted for the indicated anti-
bodies. Tubulin was probed and used as control for equal protein loading. 
One representative experiment out of 3 is given.
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